Curcumin may reduce concentration of certain cytokines in critically ill patients, says new study

July 16, 2020

A recently published study looked at the effects of a branded curcumin extract on serum cytokine concentration in critically-ill patients.

A recently published study looked at the effects of a branded curcumin extract (Curcumin C3 Complex from Sabinsa; East Windsor, NJ) on serum cytokine concentration in critically-ill patients. In the study, 62 critically ill patients between the ages of 18 and 65 with traumatic brain injury (TBI) were randomized to receive either placebo or 500 mg of the curcumin supplement in addition to routine treatment for seven days. Researchers measured the levels of serum leptin and adiponectin at baseline and at the end of the trial.

Results showed that compared to baseline, both supplementation with curcumin and placebo reduced serum leptin levels by 47.1% and 22.8%, respectively. However, the magnitude of change was greater in the curcumin group. No significant change in adiponectin was observed.

“We are happy to see the utility of C3 Complex with BioPerine in controlling the expression of cytokines in TBI patients,” said Sabinsa founder and chairman Muhammed Majeed, PhD, in a press release. “It is heartening to note that there were only benefits and no adverse side effects for this group of subjects, further attesting to our ingredient's safety.”